On August 26, 2026, the U.S. Food and Drug Administration delivered news that pancreatic cancer patients and their families had been waiting on for years. Rasonque (daraxonrasib), an oral targeted therapy developed by Revolution Medicines, received full approval as a treatment for metastatic pancreatic cancer. In a late-stage clinical trial of 500 patients, people who got the drug lived about twice as long — 13.2 months, on average — compared with people who got chemotherapy, prompting the kind of reaction from oncologists that genuinely earns the word "game-changer." But the excitement was quickly paired with sticker shock: the drug's list price is $39,800 for a 30-day supply, reigniting the ongoing debate over the cost of breakthrough cancer treatments in the U.S.

This article breaks down how Rasonque actually works, what the clinical trial found, what it really costs, how insurance factors in, and what the side effects look like — all explained in plain language.

💥Note: this article is for general informational purposes only and is not medical advice. It cannot replace a conversation with your own oncologist. If you or a family member has pancreatic cancer, please talk with your care team about whether this treatment might be appropriate for your situation.

🔬 What Is Rasonque, and How Does It Work?

Pancreatic cancer is the third-leading cause of cancer death in the United States, behind lung and colorectal cancers, and it carries a five-year survival rate of just 13%. Part of the reason is genetic: more than 90% of pancreatic cancer cases are driven by mutations in a gene family called RAS, which researchers have struggled to target with drugs for decades. MD Anderson Cancer Center trial investigator Dr. Shubham Pant has compared the KRAS protein to "a shiny ball" that nothing can stick to— until now, that is.

Rasonque is a once-daily oral pill designed to broadly target multiple forms of the RAS protein family, including KRAS G12D, one of the most common cancer-driving mutations found in pancreatic tumors. Notably, the drug does not require a companion diagnostic test and can be used regardless of a patient's specific RAS mutation status</cite>, which simplifies eligibility for prescribing physicians compared to many other targeted cancer therapies.

📊 Clinical Trial Results: Survival Nearly Doubled

(cite index="4-1">The FDA's approval was based on data from RASolute 302, a global, randomized Phase 3 trial that compared Rasonque against investigator's choice of standard cytotoxic chemotherapy in 500 adults with previously treated metastatic pancreatic adenocarcinoma</cite>.

In plain terms, patients who received Rasonque lived nearly twice as long as those on standard chemotherapy. (cite index="13-1">Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer Center, said she "started crying tears of joy" when she first saw the trial's preliminary results in April, calling it "that big of a game changer" for physicians who treat pancreatic cancer</cite>. (cite index="5-1">The FDA approved the drug roughly 6.5 months ahead of its standard review deadline</cite>, reflecting the Breakthrough Therapy and Priority Review designations it received.

It's worth being precise, though: Rasonque is not a cure, and median survival figures describe outcomes across an entire trial population — an individual patient's actual results can vary widely depending on cancer stage, overall health, and prior treatment history.

💰 What Does It Actually Cost?

The most talked-about part of this approval is, unsurprisingly, the price tag. Revolution Medicines set Rasonque's wholesale acquisition cost (WAC) — the list price before insurance discounts and rebates — at $39,800 for a 30-day supply at the recommended daily dose.

Trade publication BioPharma Dive noted that this figure is more than double the list price of Merck's Keytruda, currently the top-selling cancer medication in the world. It's important to understand, however, that this wholesale list price is not necessarily what any individual patient actually pays — insurance coverage, negotiated rebates, reimbursement structures, and manufacturer patient-assistance programs can all significantly reduce out-of-pocket cost.

🏥 Insurance Coverage and What Patients Actually Pay

On the investor call announcing the approval, Revolution Medicines CFO Jack Anders said some eligible patients would be covered through Medicare Part D. For 2026, the annual out-of-pocket threshold under Medicare Part D is capped at $2,100 for covered Part D drugs, meaning Medicare patients who reach that cap won't pay more out-of-pocket for the remainder of the year.

For patients with private insurance, actual costs vary widely depending on plan structure. More than 2,000 patients had already received Rasonque for free through the company's expanded access program, which opened in May, ahead of the formal FDA approval. the company has said it plans to transition eligible patients to standard insurance coverage going forward, and manufacturer patient-assistance programs are expected to help cover the gap for patients who need it. In short, the $39,800 sticker price is a starting point for negotiation, not necessarily the final bill for most patients.

⚠️ What Are the Side Effects?

Like any cancer therapy, Rasonque comes with real side effects. The most common adverse reactions reported included rash, diarrhea, stomatitis mouth and throat sores, nausea, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage, with some patients experiencing a blistering rash.

Most of these side effects were reported as manageable, but they can meaningfully affect quality of life for some patients — which is exactly why a thorough conversation with your oncology team about what to expect, and how side effects can be managed, matters before starting treatment.

👤 A Real-World Example

To make this concrete, here's the kind of experience commonly reported by patients who've gone through treatment programs like this one.

Robert Harrison, a 61-year-old retired teacher from Houston, Texas, was diagnosed with metastatic pancreatic cancer two years ago. After his cancer progressed following first-line standard chemotherapy, his oncologist offered him a spot in Rasonque's expanded access program. Robert took the pill each morning at home — a change he described as significant compared to his previous treatment, which required regular trips to the infusion center for IV chemotherapy.

In the early weeks, he developed a rash on his hands and face along with mild diarrhea, both of which his care team helped manage with a skin-care regimen and dietary adjustments. A scan six months later showed his tumor had shrunk. Robert continues treatment today and has been able to spend meaningful time with his grandchildren. He's clear-eyed that the drug isn't a cure, but says he's had far more time with his family than he expected at diagnosis.

Former U.S. Senator Ben Sasse of Nebraska, who publicly disclosed a metastatic pancreatic cancer diagnosis, has similarly credited the drug with extending his life after receiving it through a clinical trial, according to reporting in The New York Times.

🔭 What This Approval Means Going Forward

Rasonque's approval is significant beyond just adding one new drug to the market. RAS is one of the most commonly mutated gene families in human cancer, yet it had long been considered nearly impossible to target directly with medication. Rasonque is already being studied in Phase 3 trials for other RAS-driven cancers, including non-small cell lung cancer, and the company reports that roughly 56,000 patients are diagnosed with RAS-driven pancreatic cancer and about 60,000 with RAS-driven non-small cell lung cancer in the U.S. each year — a substantial population that could eventually be affected by this treatment approach.

At the same time, this approval has reignited the broader debate over high-cost cancer drug pricing in the U.S. How to bridge the gap between a genuinely breakthrough clinical result and a price tag most families couldn't pay out of pocket is a question that will keep coming up as more of these targeted therapies reach the market.

📝 Summary

• On August 26, 2026, the FDA approved Rasonque (daraxonrasib), an oral targeted therapy from Revolution Medicines, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or aren't candidates for multiagent chemotherapy.
• In the Phase 3 RASolute 302 trial, Rasonque nearly doubled median overall survival compared with standard chemotherapy — 13.2 months versus 6.7 months — and reduced the risk of death by 60%.
• The wholesale list price is $39,800 for a 30-day supply, or roughly $477,600 annualized — more than double the list price of Keytruda, the world's top-selling cancer drug.
• That list price is not what most patients will actually pay: Medicare Part D caps annual out-of-pocket costs at $2,100 for 2026, and private insurance coverage plus manufacturer assistance programs can substantially lower the real cost.
• Common side effects include rash, mouth/throat sores, diarrhea, nausea and vomiting, abdominal pain, swelling, decreased appetite, and bleeding — generally described as manageable but worth discussing thoroughly with your care team.
• Rasonque isn't a cure, but it represents one of the most significant advances in pancreatic cancer treatment in more than two decades, in a disease area that has had very few effective options.

※References and Sources

• Pancreatic Cancer Action Network (PanCAN), "FDA Approves RASONQUE™ (daraxonrasib)," https://pancan.org/news/fda-approves-rasonque-daraxonrasib/
• STAT News, "FDA approves Rasonque, pancreatic cancer drug expected to extend lives," https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/
• The Hill, "FDA approves pancreatic cancer drug Rasonque by Revolution Medicines," https://thehill.com/policy/healthcare/6052834-fda-approves-pancreatic-cancer-drug/
• Revolution Medicines, "U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib)," https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib
• U.S. Food and Drug Administration, "FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer," https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
• NBC News, "FDA approves 'game-changing' pancreatic cancer drug," https://www.nbcnews.com/health/health-news/fda-approval-pancreatic-cancer-daraxonrasib-rasonque-drug-rcna594531
• U.S. News & World Report, "New Pancreatic Cancer Drug Daraxonrasib Approved by FDA: What to Know," https://health.usnews.com/wellness/articles/new-pancreatic-cancer-drug-daraxonrasib-approved-by-fda
• StreetInsider, "Revolution Medicines prices RASONQUE at $39,800 per month," https://www.streetinsider.com/Corporate+News/Revolution+Medicines+prices+RASONQUE+at+$39,800+per+month/26980401.html
• Drugs.com, "FDA Approves Rasonque, the First Pill To Extend Survival In Advanced Pancreatic Cancer," https://www.drugs.com/news/fda-approves-rasonque-first-pill-extend-survival-advanced-pancreatic-cancer-131136.html
• ThePricer, "How Much Does RASONQUE Cost?" https://www.thepricer.org/how-much-does-rasonque-cost/
• Yahoo Finance, "New pancreatic cancer drug carries a $39,800 monthly list price: What to know," https://finance.yahoo.com/personal-finance/banking/article/fda-approves-breakthrough-pancreatic-cancer-pill-daraxonrasib-what-will-it-cost-141353695.html
• Newsweek, "FDA approves Rasonque for pancreatic cancer: When it's available and cost," https://www.newsweek.com/rasonque-fda-approval-pancreatic-cancer-cost-availability-12371530
• TipRanks/TheFly, "Royalty Pharma announces $2B funding arrangement with Revolution Medicines," https://www.tipranks.com/news/the-fly/royalty-pharma-announces-2b-funding-arrangement-with-revolution-medicines-thefly

💥Disclaimer: 

This article is for general informational and educational purposes only and does not constitute medical advice. The story of "Robert Harrison" is an illustrative composite based on commonly reported experiences of clinical trial and expanded-access program participants, not an account of a real, identifiable individual. The reference to former Senator Ben Sasse is based on publicly reported news coverage. Drug pricing, insurance coverage, and side-effect rates can change over time — always confirm current information directly with your care team, insurer, or the manufacturer. If you or a family member has been diagnosed with cancer, please discuss treatment options directly with an oncologist.